Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

The emerging approach of neoadjuvant immunotherapy for solid cancers has set the ground for the integration of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibitors into the neoadjuvant setting of head and neck squamous cell carcinoma (HNSCC) treatment.

Objective

To assess the reported efficacy and safety of neoadjuvant immunotherapy for resectable HNSCC.

Data sources and study selection

Electronic databases, including PubMed (MEDLINE), Embase, the Cochrane Library, and ClinicalTrials.gov were systematically searched for published and ongoing cohort studies and randomized clinical trials that evaluate neoadjuvant immunotherapy for resectable HNSCC. The search results generated studies from 2015 to July 2021.

Data extraction and synthesis

Tw

SUBMITTER: Masarwy R 

PROVIDER: S-EPMC8414366 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature